Yearly Archives: "2015"

International Day of Persons with Disabilities, 2015
The White House  BY THE PRESIDENT OF THE UNITED STATES OF AMERICA A Proclamation The United States has long been a leading voice [...]
John F. Kurtzke, MD, remembered
It is with profound sadness that the Administration and the Board of Governors of the Consortium of Multiple Sclerosis Centers report the [...]
Pregnancy hormone could keep multiple sclerosis at bay
Taking a pregnancy hormone staves off multiple sclerosis relapses, a small clinical trial suggests. The results hint at a potential [...]
Trigeminal neuralgia, type of nerve pain, is an early multiple sclerosis symptom
Trigeminal neuralgia affects the fifth cranial nerve, trigeminal, which is responsible for the sensation in the face involved with biting [...]
Exploring new paths for the treatment of multiple sclerosis
(Edmonton) Research from the University of Alberta's Faculty of Medicine & Dentistry is trailblazing a potential new pathway for the [...]
CMSC issues position statement on Aaccess to medications to treat symptoms of multiple sclerosis
Consortium of Multiple Sclerosis Centers Issues Position Statement on Access to Medications to Treat Symptoms of MS (Hackensack, NJ, [...]
Biogen reports top-line results from phase 3 study evaluating Natalizumab in SPMS
Wednesday, October 21, 2015 7:31 am EDT CAMBRIDGE, Mass.--(BUSINESS WIRE)--The Phase 3 ASCEND study investigating natalizumab in the [...]
EMD Serono announces publication of PRISMS-15 year follow-up study using Rebif in RRMS
Rockland, Massachusetts, October 12, 2015 – EMD Serono, the U.S. biopharmaceutical business of Merck KGaA, Darmstadt, Germany, today [...]
Treatment effects maintained over 5 years in patients with RRMS who received Lemtrada
Thursday, October 8, 2015 1:00 am EDT CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, aSanofi company, today announced positive new [...]
Genentech’s Ocrelizumab show positive pivotal study results in both RRMS and PPMS
Genentech’s Ocrelizumab First Investigational Medicine to Show Positive Pivotal Study Results in Both Relapsing and Primary Progressive [...]

CMSC provides leadership in clinical research and education; develops vehicles to share information and knowledge among members; disseminates information to the health care community and to persons affected by MS.

Contact Us
Contact Us





I have a question about

First

Last




Feel Free To contact Us
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam molestie, tellus id pellen tesque feugiat, sem sem cursus orci, a placerat ante ante nec massa. consectetuer adipiscing elit.

+1-222-333-4444

New York, NY 10123 USA

Mon - Sat 9:00 AM